| Excerpt | Reference |
|---|
| "The development of myeloid metaplasia is assumed to be secondary to chronic hematopoietic insufficiency." | ( Giger, A; Meuret, G; Schmid, U; Senn, HJ, 1977) |
| "Idiopathic myelofibrosis is reviewed from several aspects." | ( Weinstein, IM, 1991) |
| "IHS with myelofibrosis is usually considered as unresponsive to corticotherapy." | ( Capodano, AM; Fossat, C; Guitard, AM; Michel, G; Mozziconacci, MJ; Perrimond, H; Scheiner, C; Thuret, I, 1991) |
| "Idiopathic myelofibrosis is a disease of unknown cause characterized by systemic marrow fibrosis and extramedullary hematopoiesis." | ( Iwahara, Y; Kataoka, R; Miyoshi, I; Muneishi, H; Uemura, Y, 1990) |
| "Acute myelofibrosis is often associated with acute megakaryoblastic leukemia (AMKBL)." | ( Fujisaki, Y; Kohgo, Y; Mahara, K; Mogi, Y; Niitsu, Y; Ogura, M; Saito, H; Terui, T; Urushizaki, Y; Watanabe, N, 1990) |
| "Acute myelofibrosis is a rare and still ill-defined disease." | ( Frickhofen, N; Heil, G; Heimpel, H; Hertenstein, B; Kurrle, E, 1990) |
| "Acute myelofibrosis is a rare hematologic malignancy which usually follows a rapidly progressive, fatal course." | ( Marino, GG; Robinson, WL, 1989) |
| "Two cases of myelofibrosis are reported, one corresponding to a chronic idiopathic myelofibrosis and another to an acute myelofibrosis or megakaryoblastic leukemia (AMGL)." | ( García Díez, I; Martínez, R; Palomera, L, 1989) |
| "Bone marrow fibrosis is a characteristic finding in agnogenic myeloid metaplasia and in the spent phase of polycythemia vera." | ( Kumar, A; Talarico, L; Weintraub, LR; Wolf, BC, 1989) |
| "Myelofibrosis is an idiopathic condition of man associated with increased deposition of bone marrow collagen." | ( Fruchtman, SM, 1984) |
| "This myelofibrosis is similar to that found in most of myeloproliferative disorders at some step of evolutivity." | ( Caen, JP; Cywiner-Golenzer, C; Drouet, L; Flandrin, G; Praloran, V; Trehen, C, 1981) |
| "A patient with idiopathic myelofibrosis is reported who developed a drug fever after treatment with hydroxyurea, a generally effective and well-tolerated drug in chronic myeloproliferative syndromes." | ( Fickers, MM; Pannebakker, MA; Starmans-Kool, MJ, 1995) |
| "Agnogenic myeloid metaplasia is very rare in children." | ( Cetingül, N; Nisli, G; Oztop, S; Soydan, S; Yener, E, 1994) |
| "Primary myelofibrosis is rare in infants and children; its association with auto-immune markers has only been reported in adults." | ( Adam, M; Bangui, A; Leverger, G; Pilorget, H, 1996) |
| "Idiopathic myelofibrosis is the least common and carries the worst prognosis of the chronic myeloproliferative disorders." | ( Reilly, JT, 1998) |
| "Acute myelofibrosis is a rare, malignant hematological disorder of unknown etiology with an inevitably fatal outcome." | ( Aigner, R; Beham-Schmid, C; Linkesch, W; Olipitz, W; Raith, J; Sill, H, 2000) |
| "In this context, myelofibrosis is secondary to plasmocyte invasion of the bone marrow and regresses, or disappears, following specific treatment of the myeloma." | ( Boucher, E; De Revel, T; Nedellec, G; Samson, T; Souleau, B; Védrine, L, 2002) |
| "Idiopathic myelofibrosis is a chronic myeloproliferative disorder being featured by progressive accumulation of connective tissue in concert with marked neovascularization (angiogenesis) of the bone marrow." | ( Hasselbalch, HC, 2003) |
| "Reticulin-stained bone marrow fibrosis is associated with a poor prognosis in patients with chronic myelogenous leukemia (CML)." | ( Bueso-Ramos, CE; Cortes, J; Giles, F; Kantarjian, H; Medeiros, LJ; O'Brien, S; Rios, MB; Talpaz, M, 2004) |
| "Myelofibrosis is associated historically with a poor prognosis in patients with chronic myelogenous leukemia (CML)." | ( Bueso-Ramos, CE; Cortes, J; Faderl, S; Giles, F; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Wierda, W, 2005) |
| "Myelofibrosis is usually observed in myeloproliferative disorders, such as chronic myeloid leukemia." | ( Iguchi, T; Ito, Y; Kimura, Y; Miyazawa, K; Mukai, K; Ohyashiki, K; Okabe, S; Serizawa, H; Sumi, M; Takaku, T, 2005) |
| "Myelofibrosis with myeloid metaplasia is defined as a myeloproliferative disorder characterized by leukoerythroblastosis, tear drop erythrocytes, extramedullary hematopoesis and varying degree of myelofibrosis." | ( Gulati, S; Jain, V; Kabra, M; Kalra, V; Maheshwari, A, 2005) |
| "Myelofibrosis is an uncommon phenomenon associated with a variety of neoplastic and inflammatory processes." | ( Corcoran, KE; Harrison, JS; Joshi, D; Rameshwar, P; Sophacleus, C, 2006) |
| "Intense myelofibrosis is rarely associated with de novo acute myeloid leukaemia (AML) except in acute megakaryoblastic leukaemia (AML-M7) where there is diffuse marrow fibrosis as a consequence of proliferation of neoplastic myeloid cells." | ( Fadilah, SA; Leong, CF; Raja-Zahratul-Azma, RS, 2006) |
| "Myelofibrosis is a rare childhood myeloproliferative disorder." | ( Choudhry, VP; Naithani, R; Tyagi, S, 2008) |
| "Idiopathic myelofibrosis is a chronic myeloproliferative disorder characterized by excessive connective tissue deposition in the bone marrow." | ( Mahajan, D; Nigam, S; Singh, DK; Singh, T, 2008) |
| "Myelofibrosis is commonly seen in patients with chronic myeloproliferative diseases and sometimes in myelodysplastic syndrome, acute leukaemia and lymphoproliferative diseases." | ( Dahl, IM; Engström-Laurent, A; Hultdin, M; Sundström, G, 2010) |
| "Primary myelofibrosis is a clonal haematopoietic stem cell disease, characterised by marrow stromal fibrosis, extramedullary haematopoiesis, splenomegaly, hepatomegaly and progressive cytopenia." | ( de Witte, T; Holle, N; Mandigers, C; Raymakers, R; Schaap, N, 2010) |
| "Myelofibrosis is a Philadelphia chromosome–negative myeloproliferative neoplasm associated with cytopenias, splenomegaly, poor quality of life, and shortened survival." | ( Bradley, EC; Cortes-Franco, J; Erickson-Viitanen, S; Estrov, Z; Fridman, JS; Kantarjian, H; Levy, R; Mesa, RA; Pardanani, AD; Tefferi, A; Thomas, DA; Vaddi, K; Verstovsek, S, 2010) |
| "Myelofibrosis is a myeloid malignancy associated with anemia, splenomegaly, and constitutional symptoms." | ( Cortes, JE; Gilliland, DG; Gotlib, JR; Jamieson, C; Pardanani, A; Shorr, J; Silverman, MH; Stone, RM; Talpaz, M; Tefferi, A, 2011) |
| "Primary myelofibrosis is a chronic myeloproliferative neoplasm characterized by cytopenias, leukoerythroblastosis, extramedullary hematopoiesis, hepatosplenomegaly and bone marrow fibrosis." | ( Ataya, R; Bertuch, AA; DeLario, MR; Lopez-Terrada, D; Sheehan, AM; Vega, C; Venkateswaran, L; Webb, CR, 2012) |
| "Primary myelofibrosis is a myeloproliferative disorder characterized by bone marrow fibrosis, abnormal cytokine expression, splenomegaly and anemia." | ( Colomba, C; Lalicata, F; Rubino, R; Siracusa, L; Titone, L; Tolomeo, M; Trizzino, M, 2012) |
| "Myelofibrosis is a myeloproliferative neoplasm characterized by bone marrow fibrosis and extramedullary hematopoiesis." | ( Ganetsky, A, 2013) |
| "Myelofibrosis is the most serious of the 3, associated with shortened survival (median survival, 5-7 years); bone marrow failure with anemia; progressive splenomegaly; and chronic, burdensome symptoms, including fatigue, night sweats, itching, abdominal discomfort, loss of appetite/early satiety, unintentional weight loss, and bone, chest, and abdominal pain." | ( Verstovsek, S, 2013) |
| "Myelofibrosis is a hematological malignancy with a median survival of approximately 5 to 7 years." | ( Hoffman, R; Mascarenhas, J, 2013) |
| "Primary myelofibrosis is a malignant myeloproliferative disease." | ( Bruserud, Ø; Delabie, J; Ghanima, W; Knutsen, H, 2013) |
| "Primary myelofibrosis is a member of the myeloproliferative neoplasms, a diverse group of bone marrow malignancies." | ( Bhalla, KN; Champlin, RE; Harrison, C; Hoffman, R; Mascarenhas, JO; Orazi, A, 2013) |
| "Primary myelofibrosis is a clonal disease of chronic myeloproliferative neoplasm, and is a progressive clinical course with short median survival of less than 5 years after diagnosis." | ( Chu, SC; Huang, WH; Kao, RH; Li, MS; Wang, TF; Wu, YF, 2014) |
| "However, as myelofibrosis is not a disease with spontaneous remissions, even non-randomized trials carry weight." | ( Birgegård, G, 2014) |
| "Myelofibrosis is characterized by progressive cytopenias, bone marrow fibrosis, splenomegaly and severe constitutional symptoms." | ( Akashi, K; Amagasaki, T; Depei, W; Du, X; Eom, KS; Gopalakrishna, P; Handa, H; Hou, HA; Hou, M; Hu, Y; Ito, K; Jianyong, L; Jie, J; Jung, CW; Kim, JS; Li, J; Liu, T; Ohishi, K; Okamoto, S; Oritani, K; Park, S; Saito, S; Shih, LY; Takenaka, K; Tauchi, T; Wang, MC; Xiao, Z; Zhou, D, 2015) |
| "Myelofibrosis is a haematopoietic stem cell neoplasm characterized by bone marrow inflammation, reactive marrow fibrosis and extramedullary haematopoiesis." | ( Alchalby, H; Apostolova, I; Bannas, P; Bengel, FM; Derlin, T; Kröger, N; Triviai, I; Veldhoen, S, 2015) |
| "Myelofibrosis is a rare hematopoietic stem cell neoplasm leading to marked bone marrow fibrosis and ineffective hematopoiesis." | ( Büsche, G; Derlin, T; Kröger, N, 2015) |
| "Myelofibrosis is a rare clonal hematopoietic stem cell disorder characterized by chronic myeloproliferation, atypical megakaryocytic hyperplasia, and potential leukemic transformation." | ( Clauditz, TS; Derlin, T; Kröger, N, 2015) |
| "Myelofibrosis is characterized by splenomegaly and debilitating constitutional symptoms that negatively impact patients' quality of life." | ( Ali, S; Andrews, C; Chacko, J; Clark, RE; Dawson, MK; Farquharson, M; Garg, M; Harrison, C; Knapper, S; Mead, AJ; Milojkovic, D; Yin, J, 2015) |
| "Myelofibrosis is a bone marrow disorder characterized by excessive production of reticulin and collagen fiber deposition caused by hematological and non-hematological disorders." | ( Anand, V; Martí-Carvajal, AJ; Solà, I, 2015) |
| "Primary myelofibrosis is a stem cell-derived clonal malignancy characterized by unchecked proliferation of myeloid cells, resulting in bone marrow fibrosis, osteosclerosis, and pathologic angiogenesis." | ( Daver, N; Khoury, JD; Nazha, A; Rampal, RK, 2015) |
| "Primary myelofibrosis is one of the chronic myeloproliferative disorders characterized by bone marrow fibrosis associated with extramedullary hematopoiesis and osteosclerosis." | ( Blank, RD; Kristianto, J; Sitwala, K; Yachoui, R, 2015) |
| "Primary myelofibrosis is a unique entity among BCR-ABL-negative myeloproliferative diseases, manifesting as bone marrow fibrosis and pancytopenia." | ( Berger, K; Pu, JJ; Shantzer, L, 2017) |
| "Myelofibrosis is a BCR-ABL-negative myeloproliferative neoplasm characterized by abnormal hematopoiesis." | ( Highsmith, K; Leung, M; Rexwinkle, A, 2017) |
| "Myelofibrosis is a chronic and progressive myeloproliferative neoplasm characterized by anemia, splenomegaly, debilitating symptoms and leukemic transformation." | ( Goldberg, JD; Hochman, T; Hoffman, R; Lu, M; Mascarenhas, J; Najfeld, V; Newsom, C; Petersen, B; Sandy, L; Ye, F; Yoon, J; Zhang, D, 2017) |
| "Myelofibrosis is an indicator of poor prognosis in myeloproliferative neoplasms (MPNs), but the precise mechanism(s) contributing to extracellular matrix remodeling and collagen deposition in the bone marrow (BM) niche remains unanswered." | ( Epling-Burnette, PK; Han, Y; Levine, RL; Ren, X; Shao, Z; Wei, M; Yue, L; Zhang, L, 2017) |
| "Although bone marrow fibrosis is a lethal condition, its underlying mechanism is not fully understood." | ( Akioka, T; Fujimoto, M; Fumimoto, A; Hatooka, J; Hiraoka, N; Iwaki, K; Masuda, Y; Miyoshi, T; Nakayama, S; Nishimura, Y; Nishiwaki, U; Tsuji, M; Yokote, T, 2017) |
| "Although myelofibrosis is mainly associated with myeloproliferative neoplasms (MPN), especially primary myelofibrosis (PMF), a variety of hematological malignancies, including acute myeloid leukemia, multiple myeloma and malignant lymphoma, also cause myelofibrosis with markedly varying degrees of severity." | ( Kirito, K; Koshiishi, M; Kumagai, T; Mitsumori, T; Nakajima, K; Ooishi, S; Satoh, Y; Sueki, Y, 2017) |
| "Primary myelofibrosis is characterized by bone marrow fibrosis, splenomegaly and presence of JAK-2 V617F mutation in more than 90% of patients." | ( Dasanu, CA; Del Rosario, M; Tsai, H, 2018) |
| "Bone marrow fibrosis is a critical component of primary myelofibrosis (PMF)." | ( Decker, M; Ding, L; Lee, Y; Leslie, J; Liu, Q; Martinez-Morentin, L; Wang, G, 2017) |
| "Myelofibrosis is a chronic myeloproliferative neoplasm characterised by splenomegaly, cytopenias, bone marrow fibrosis, and debilitating symptoms including fatigue, weight loss, and bone pain." | ( Harrison, CN; Jourdan, E; Kiladjian, JJ; Lager, J; Mesa, RA; Passamonti, F; Schaap, N; Schouten, HC; Shun, Z; Silver, RT; Talpaz, M; Tiu, RV; Vannucchi, AM; Winton, E; Zachee, P; Zweegman, S, 2017) |
| "Myelofibrosis is a myeloproliferative neoplasm that is characterized by splenomegaly, profound symptom burden, and cytopenias." | ( Camoriano, J; Dueck, A; Gano, K; Gowin, K; Hoffman, R; Kosiorek, H; Mascarenhas, J; Mesa, R; Palmer, J; Reeder, C; Tibes, R, 2017) |
| "Bone marrow fibrosis is a critical component of primary myelofibrosis in which normal bone marrow tissue and blood-forming cells are gradually replaced with scar tissue." | ( Almeida, VM; Andreotti, JP; Azevedo, PO; Birbrair, A; Borges, IT; Guerra, DAP; Lousado, L; Mintz, A; Paiva, AE; Prazeres, PHDM; Santos, GSP; Sena, IFG; Souto, L, 2017) |
| "Primary myelofibrosis is encountered with the myeloproliferative diseases and is the least prevalent among women of childbearing age." | ( Bohîlţea, RE; Cîrstoiu, MM; Dimitriu, M; Ionescu, CA; Niculescu-Mizil, E; Turcan, N; Vlădăreanu, AM; Voican, I, 2017) |
| "Primary myelofibrosis is a chronic myeloproliferative neoplasm that may cause debilitating symptoms, which can be improved with the use of Ruxolitinib, a Janus kinase 2 inhibitor." | ( Abu Saleh, OM; Dioverti, MV; Tande, AJ, 2018) |
| "Primary myelofibrosis is a myeloproliferative neoplasm associated with significant morbidity and mortality, for which effective therapies are lacking." | ( Chen, M; Chen, W; Fedoriw, Y; Huang, L; Kim, J; Lefkowitz, RJ; Premont, RT; Price, T; Rein, LA; Sipkins, D; Theriot, B; Walker, JK; Wisler, JW; Yang, H, 2017) |
| "Myelofibrosis is a hematologic malignancy characterized by splenomegaly and debilitating symptoms." | ( Al-Fayoumi, S; Callahan, JA; Daly, R; Drummond, M; Gerds, AT; Gotlib, J; Granston, T; Gupta, V; Harrison, C; Hoffman, R; Jamieson, C; Mascarenhas, J; Mesa, R; Pristupa, A; Singer, JW; Stein, B; Szoke, A; Talpaz, M; Verstovsek, S, 2018) |
| "Autoimmune myelofibrosis is a distinct clinicopathological entity that occurs with autoimmune disorders." | ( Belfeki, N; Declerck, D; Diamantis, S; Shankarasivam, G, 2019) |
| "Primary idiopathic myelofibrosis is a clonal disorder arising from the neoplastic transformation of early haematopoietic stem cells leading to abnormal fibrous tissue within bone marrow." | ( Das, T; Raval, V; Sudana, P, 2019) |
| "Myelofibrosis is a BCR-ABL1-negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, constitutional symptoms, leukemic progression, and shortened survival." | ( Harrison, CN; Mesa, RA; Schaap, N, 2020) |
| "Myelofibrosis (myelofibrosis) is a deadly blood neoplasia with the worst prognosis among myeloproliferative neoplasms (MPN)." | ( Dutta, A; Le, BT; Mohi, G; Nath, D; Yang, Y, 2021) |
| "Myelofibrosis is a myeloproliferative neoplasm associated with constitutional symptoms, increasing splenomegaly, and worsening cytopenias." | ( Ianotto, JC; Kiladjian, JJ; Luque Paz, D; Orvain, C; Riou, J; Sureau, L; Ugo, V, 2021) |
| "Myelofibrosis is characterized by stem cell-derived clonal proliferation potentially resulting in bone marrow fibrosis." | ( Fujishima, F; Fukuhara, N; Joh, K; Sasano, H; Taniuchi, S; Watanabe, H, 2022) |
| "Myelofibrosis is one of the classical Philadelphia chromosome-negative myeloproliferative neoplasms characterized by progressive marrow failure and chronic inflammation." | ( England, J; Gupta, V, 2021) |
| "Myelofibrosis is a rare bone marrow disorder associated with a high symptom burden, poor prognosis, and shortened survival." | ( Benghiat, FS; Devos, T; Granacher, N; Havelange, V; Selleslag, D, 2022) |
| "Primary myelofibrosis is a haematopoietic stem cell neoplasm resulting in ineffective haematopoiesis and bone marrow fibrosis." | ( Andleeb, M; Hussain, S; Qamar Uz Zaman, A; Raza, S; Siddiqui, T; Zaheer, R, 2022) |
| "Myelofibrosis is a myeloproliferative neoplasm characterized by splenomegaly, debilitating constitutional symptoms and bone marrow failure." | ( Mesa, R; Tremblay, D, 2022) |
| "Primary myelofibrosis is a chronic inflammatory disease of the bone marrow." | ( Chen, L; Huang, Z; Li, X; Luo, Q; Zhao, Q, 2022) |
| "Primary myelofibrosis is a rare type of myeloproliferative neoplasm with an annual incidence rate of 0." | ( Chew, LP; Goh, A; Leong, TS; Ong, JHL; Tang, ASO, 2023) |
| Excerpt | Reference |
|---|
| "A female patient showed signs of osteomyelofibrosis after being treated for 70 months." | ( Jäckle, B; Maas, D; Raif, W; Schramm, A; Schubothe, H, 1979) |
| "One patient with myelofibrosis improved dramatically with placebo therapy alone, no longer requiring frequent transfusions because of a hemoglobin level increase from 5." | ( Amsden, TW; Branda, RF; Jacob, HS, 1977) |
| "A case of acute myelofibrosis occurring in the course of long-term chlorambucil therapy for cardiac manifestations of progressive systemic sclerosis (PSS) is reported." | ( Chung, KB; Gisser, SD, 1979) |
| "A 64 year-old female patient of idiopathic myelofibrosis (IMF), who had had rapidly progressing massive splenomegaly and severe pancytopenia refractory to blood transfusion, was treated with PSL 0." | ( Ikeda, Y; Kubo, A; Masuda, Y; Michikawa, N; Ogawa, T; Tanosaki, R; Uchida, H, 1992) |
| "A 69-year-old man with agnogenic myeloid metaplasia was treated with interferon-alpha 2 as part of a Phase II clinical trial." | ( Buckley, P; Duffy, TP; Radin, AI, 1991) |
| "IHS with myelofibrosis is usually considered as unresponsive to corticotherapy." | ( Capodano, AM; Fossat, C; Guitard, AM; Michel, G; Mozziconacci, MJ; Perrimond, H; Scheiner, C; Thuret, I, 1991) |
| "A 68-yr-old male with agnogenic myeloid metaplasia was given phosphorus-32-colloidal chromic phosphate intrapericardially for the treatment of malignant pericardial effusion." | ( McDermott, RL; Sprengelmeyer, JT, 1990) |
| "A patient with secondary myelofibrosis associated with prostatic cancer gained hematologic remission after hormone therapy." | ( Fukuchi, M; Ishimura, J, 1990) |
| "Two cases of idiopathic myelofibrosis of childhood were treated with intravenous methylprednisolone." | ( Ozsoylu, S; Ruacan, S, 1986) |
| "The case of a patient with myelofibrosis who developed polycythaemia vera after corticosteroid therapy, splenectomy and Busulphan therapy is reported." | ( Bizzi, B; Leone, G; Marra, R; Pagano, L; Rabbitti, C; Storti, S; Teofili, L, 1988) |
| "Three patients with chronic idiopathic myelofibrosis have responded to busulfan treatment with an excellent hematologic remission and reversal of myelofibrosis and myeloid metaplasia." | ( Chang, JC; Gross, HM, 1988) |
| "Bone marrow myelofibrosis may be another delayed treatment effect of this class of drugs." | ( Fehir, KM; McKenney, SA, 1986) |
| "A patient with myelofibrosis transforming into acute non-lymphocytic leukaemia (ANLL) was treated with low doses of cytosine arabinoside (ARA-C)." | ( Ahlbom, G; Jensen, MK; Johansen, P, 1986) |
| "12 patients with symptomatic chronic myelofibrosis were treated with either busulphan or 6-thioguanine." | ( Manoharan, A; Pitney, WR, 1984) |
| "The responses of 23 patients with agnogenic myeloid metaplasia (AMM) to androgen therapy were studied." | ( Besa, EC; Gardner, FH; Geller, NL; Nowell, PC, 1982) |
| "A case of myelofibrosis related to thorotrast administration is described." | ( Arnold, AG; Oelbaum, MH, 1980) |
| "A patient with idiopathic myelofibrosis is reported who developed a drug fever after treatment with hydroxyurea, a generally effective and well-tolerated drug in chronic myeloproliferative syndromes." | ( Fickers, MM; Pannebakker, MA; Starmans-Kool, MJ, 1995) |
| "The progression towards myelofibrosis (spent phase, post polycythaemia myeloid splenomegaly) increases with the duration of the disease and the frequency of transformation differs according to the type of treatment." | ( Rain, JD, 1994) |
| "This case was considered to be an acute myelofibrosis developed from myelodysplastic syndrome and worth to reporting with a review of literature, because drastic combination chemotherapy was extremely effective." | ( Fujita, H; Hirayama, M; Kohgo, Y; Kura, T; Mogi, Y; Nakaya, R; Niitsu, Y; Tsuji, N; Watanabe, N, 1993) |
| "These findings indicated that her myelofibrosis was the result of secondary hyperparathyroidism, and that this complication is potentially reversible if accurate treatment is given." | ( Harada, T; Katagiri, M; Nagahana, H; Nomura, S; Ogawa, Y; Osawa, G, 1996) |
| "A 55-year-old man with myelofibrosis was treated with natural alpha-interferon with a good hematologic response." | ( Andoh, A; Bamba, T; Fujiyama, Y; Hodohara, K; Minamiguchi, H; Nakamura, F, 1997) |
| "Improvement in bone marrow fibrosis was noted in two of five available post-treatment marrow examinations." | ( Li, CY; Silverstein, MN; Tefferi, A, 1997) |
| "A patient with myelofibrosis complicated by recurrent candidemia died despite treatment with amphotericin B and fluconazole." | ( Matsumura, M; Mori, T; Oguri, T, 1998) |
| "We report a case of fulminant myelofibrosis after administration of fludarabine in a patient diagnosed as having refractory low-grade lymphoma, progressing fatally." | ( Azaceta, G; Gutierrez, M; Palomera, L; Soria, J; Varo, MJ, 1998) |
| "The focus was on whether myelofibrosis is associated with the PEG-rHuMGDF treatment in this chemotherapy model." | ( Harada, K; Ide, Y; Imai, A; Yanagida, M, 1999) |
| "In a phase 2 study, 23 patients with myelofibrosis with myeloid metaplasia were treated with imatinib mesylate at a constant dose of 400 mg/d." | ( Ansell, SM; Call, TG; Camoriano, JK; Colon-Otero, G; Dewald, GW; Elliott, MA; Gray, LA; Hanson, CA; Kaufmann, SH; Mesa, RA; Pardanani, A; Schroeder, G; Steensma, DP; Tefferi, A, 2002) |
| "We report a case of myelofibrosis with myeloid metaplasia (MMM) that responded dramatically to oral busulfan treatment after failure of hydroxyurea." | ( Baumann, MA; Naqvi, T, 2002) |
| "Thirteen patients with idiopathic myelofibrosis (5 osteomyelosclerosis) were treated with recombinant human erythropoietin (rHuEpo) for transfusion-dependent anemia." | ( Clausen, NT; Hasselbalch, HC; Jensen, BA, 2002) |
| "In this context, myelofibrosis is secondary to plasmocyte invasion of the bone marrow and regresses, or disappears, following specific treatment of the myeloma." | ( Boucher, E; De Revel, T; Nedellec, G; Samson, T; Souleau, B; Védrine, L, 2002) |
| "A 70-year-old man with primary myelofibrosis was treated with hydroxycarbamide and blood transfusions." | ( Jonkhoff, AR; van der Valk, P; Zweegman, S, 2002) |
| "Controversial issues in chronic idiopathic myelofibrosis (IMP) are amongst others the evolution of the disease process and the influence of therapy on the dynamics of fibrosis." | ( Diehl, V; Kvasnicka, HM; Schmitt-Graeff, A; Thiele, J, 2003) |
| "A 38-year-old woman with agnogenic myeloid metaplasia complicated by the poor prognostic factors of severe osteosclerosis, prominent hepatosplenomegaly, and profound anemia was treated with FLAG chemotherapy to decrease her organomegaly before undergoing a nonmyeloablative allogeneic stem cell transplant from a matched-sibling donor." | ( Ball, ED; Bashey, A; Broome, HE; Carrier, E; Hoh, CK; Holman, P; Lane, T; Sun, C; Tanner, ML, 2003) |
| "Development of myelofibrosis in IMF is obviously due to disease progression unrelated to stage at diagnosis and not significantly influenced by treatment modalities." | ( Diehl, V; Hülsemann, R; Kvasnicka, HM; Schmitt-Gräff, A; Thiele, J, 2004) |
| "The influence of Cladribin therapy to bone marrow fibrosis in patients with hairy cell leukemia was studied." | ( Dĕdic, K; Zák, P, 2004) |
| "The effect of imatinib therapy on bone marrow fibrosis was evaluated in 40 patients with chronic-phase CML who were treated after interferon-alpha failure." | ( Bueso-Ramos, CE; Cortes, J; Giles, F; Kantarjian, H; Medeiros, LJ; O'Brien, S; Rios, MB; Talpaz, M, 2004) |
| "We present a 9-year-old girl with known myelofibrosis whose headaches were unresponsive to routine treatment." | ( Blaser, S; Gilday, D; Haidar, S; Ortiz-Neira, C; Shroff, M, 2005) |
| "The conventional treatment of myelofibrosis involves a wait-and-see approach for asymptomatic patients, oral chemotherapy for the hyperproliferative forms of the disease, androgens or erythropoietin for the anaemia, and splenectomy in selected patients." | ( Cervantes, F, 2005) |
| "Forty-four patients who had myelofibrosis with myeloid metaplasia received treatment with thalidomide in a Phase II clinical trial at a dose of 200 mg daily with escalation by 200 mg weekly until the best tolerated dose (maximum, 800 mg) was reached." | ( Albitar, M; Cortes, JE; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Pierce, S; Thomas, DA; Verstovsek, S; Zeldis, J, 2006) |
| "Here, we discuss a patient with primary myelofibrosis and related transfusion-dependent anemia who received chelation therapy with the once-daily oral iron chelator, deferasirox." | ( Alberti, D; Angelucci, E; Deplano, S; Di Tucci, AA; Murru, R; Rabault, B, 2007) |
| "We report a patient with very advanced myelofibrosis and huge splenomegaly who showed a complete hematological response to low dose thalidomide with reversal of splenomegaly and bone narrow fibrosis after 30 months of the treatment." | ( Berrebi, A; Feldberg, E; Shvidel, L; Spivak, I, 2007) |
| "Since bone marrow biopsy revealed myelofibrosis, she received anabolic hormone therapy." | ( Kubota, Y; Waki, M, 2009) |
| "Eighty-four patients with myelofibrosis-associated anemia were randomly assigned to the aforementioned treatment arms: 22, 19, 22, and 21, respectively." | ( Barosi, G; Bekele, BN; Cervantes, F; Deeg, HJ; Gale, RP; Gisslinger, H; Kantarjian, HM; Kvasnicka, HM; Mesa, RA; Paquette, RL; Passamonti, F; Rivera, CE; Roboz, GJ; Tefferi, A; Thiele, J; Vardiman, JW; Verstovsek, S; Zhang, Y, 2009) |
| "Leukemic transformation (LT) from myelofibrosis has a very poor prognosis with the current treatment strategies." | ( Andersson, BS; Bueso-Ramos, C; Champlin, RE; Ciurea, SO; de Lima, M; Giralt, S; Hosing, CM; Popat, U; Saliba, R; Verstovsek, S, 2010) |
| "Fourteen patients with myelofibrosis were treated with sunitinib at a daily continuous dose of 37." | ( Apostolidou, E; Borthakur, G; Burger, I; Kantarjian, H; Thomas, D; Verstovsek, S, 2010) |
| "Treatment options for myelofibrosis are limited." | ( Al-Ali, HK; Barbui, T; Barosi, G; Cervantes, F; Gisslinger, H; Harrison, C; Hunter, DS; Kiladjian, JJ; Knoops, L; Levy, R; McQuitty, M; Stalbovskaya, V; Vannucchi, AM; Waltzman, R, 2012) |
| "Diagnosis of post-PV myelofibrosis is established according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment criteria." | ( Passamonti, F, 2012) |
| "Hypercalcemia associated with myelofibrosis is rare, and its pathogenesis and treatment are not known." | ( Chang, J; Gru, AA; Khoury, N; Whyte, MP, 2012) |
| "COMFORT-I (Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment-I) is a double-blind, placebo-controlled phase III study evaluating ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis." | ( Catalano, JV; Deininger, MW; Erickson-Viitanen, S; Gotlib, J; Gupta, V; Hare, T; Harvey, JH; Kantarjian, HM; Levy, RS; Mesa, RA; Miller, CB; Sandor, V; Shields, AL; Silver, RT; Sun, W; Talpaz, M; Verstovsek, S; Winton, EF, 2013) |
| "The landscape of therapy for myelofibrosis (MF) is evolving at a pace not previously seen for this clonal myeloproliferative neoplasm." | ( Emanuel, R; Geyer, H; Gowin, K; Mesa, RA, 2013) |
| "In the phase 3 Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies, ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, provided substantial improvements in splenomegaly, symptoms, quality-of-life measures and overall survival compared with placebo or best available therapy." | ( Akashi, K; Amagasaki, T; Depei, W; Du, X; Eom, KS; Gopalakrishna, P; Handa, H; Hou, HA; Hou, M; Hu, Y; Ito, K; Jianyong, L; Jie, J; Jung, CW; Kim, JS; Li, J; Liu, T; Ohishi, K; Okamoto, S; Oritani, K; Park, S; Saito, S; Shih, LY; Takenaka, K; Tauchi, T; Wang, MC; Xiao, Z; Zhou, D, 2015) |
| "In the COMFORT (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy)-I study, the Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib provided significant reductions in splenomegaly, improvements in myelofibrosis (MF)-related symptoms, and a survival advantage relative to placebo in patients with intermediate-2 or high-risk MF." | ( Atallah, E; Burn, T; Gotlib, J; Gupta, V; Mascarenhas, JO; Mesa, RA; Sandor, V; Sun, W; Verstovsek, S, 2015) |
| "The prognosis of myelofibrosis is poor and treatment is mainly palliative." | ( Anand, V; Martí-Carvajal, AJ; Solà, I, 2015) |
| "We report 12 Danish myelofibrosis patients who have been treated successfully with ruxolitinib despite having low platelet counts (< 50 × 10(9)/L) during their treatment-course." | ( Bjørn, ME; Hasselbalch, HC; Holmström, MO, 2016) |
| "In the phase 3 Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment-I trial, patients with MF, post-PV MF, or post-ET MF achieved significant reductions in splenomegaly and improvements in symptoms with ruxolitinib vs placebo at week 24." | ( Burn, TC; Deininger, M; Huber, R; Paranagama, D; Radich, J; Verstovsek, S, 2015) |
| "Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm where severity as well as treatment complexity is mainly attributed to a long lasting disease and presence of bone marrow stroma alterations as evidenced by myelofibrosis, neoangiogenesis, and osteosclerosis." | ( Desterke, C; Le Bousse-Kerdilès, MC; Martinaud, C; Ruzehaji, N, 2015) |
| "Discontinuation of ruxolitinib in myelofibrosis often induces 'withdrawal syndrome' characterized by acute relapse of the disease, but this issue is not well addressed in the treatment of GvHD." | ( Ago, H; Fujii, N; Ikeda, K; Inomata, T; Mori, Y; Teshima, T; Yoshimoto, G, 2016) |
| "Patients with myelofibrosis at intermediate-1 risk according to the International Prognostic Score System are projected to a relatively long survival; nonetheless, they may carry significant splenomegaly and/or systemic constitutional symptoms that hamper quality of life and require treatment." | ( Abruzzese, E; Benevolo, G; Bergamaschi, M; Binotto, G; Bonifacio, M; Breccia, M; Buccisano, F; Cavazzini, F; Cavo, M; Crugnola, M; Cuneo, A; Heidel, FH; Isidori, A; Kallenberg, L; Latagliata, R; Martino, B; Palandri, F; Palumbo, GA; Polverelli, N; Scaffidi, L; Sgherza, N; Spinsanti, M; Tieghi, A; Tiribelli, M; Vianelli, N, 2018) |
| "The phase III COMFORT (Controlled Myelofibrosis Study With Oral JAK inhibitor Treatment)-I and COMFORT-II trials in patients with intermediate-2 or high-risk myelofibrosis (MF) showed that ruxolitinib was superior to placebo and best available therapy, respectively, for improvements in spleen volume, MF-related symptoms, and overall survival (OS)." | ( Komrokji, RS; Mesa, RA; Miller, CB; Montgomery, M; Sun, W; Verstovsek, S, 2017) |
| "A 72-year-old man with myelofibrosis started treatment with ruxolitinib." | ( Ballesta, B; Ballesta, JJ; González, H; Martín, V, 2017) |
| "Conclusion In JAKi-naïve patients with myelofibrosis, 24 weeks of momelotinib treatment was noninferior to ruxolitinib for spleen response but not for symptom response." | ( Catalano, JV; Cervantes, F; Deng, W; Devos, T; Dubowy, RL; Egyed, M; Gotlib, J; Hellmann, A; Kiladjian, JJ; Maltzman, JD; McLornan, D; Mesa, RA; Shimoda, K; Winton, EF, 2017) |
| "The treatment landscape for myelofibrosis (MF) has reached the molecular era by targeting different pathways that are implied in this myeloproliferative neoplasm." | ( Diaz, AE; Mesa, RA, 2018) |
| "Patients who had myelofibrosis and previous ruxolitinib treatment for at least 28 days who either required red blood cell transfusions while on ruxolitinib or ruxolitinib dose reduction to less than 20 mg twice a day with at least one of grade 3 thrombocytopenia, anaemia, or bleeding at grade 3 or worse, with palpable spleen of at least 5 cm and without grade 2 or greater peripheral neuropathy were included in the study." | ( Cervantes, F; Dong, H; Gupta, V; Harrison, CN; Kawashima, J; Kiladjian, JJ; Lavie, D; Maltzman, JD; Passamonti, F; Platzbecker, U; Vannucchi, AM; Verstovsek, S; Winton, EF, 2018) |
| "In patients with myelofibrosis previously treated with ruxolitinib, momelotinib was not superior to BAT for the reduction of spleen size by at least 35% compared with baseline." | ( Cervantes, F; Dong, H; Gupta, V; Harrison, CN; Kawashima, J; Kiladjian, JJ; Lavie, D; Maltzman, JD; Passamonti, F; Platzbecker, U; Vannucchi, AM; Verstovsek, S; Winton, EF, 2018) |
| "A 73-year-old man with primary myelofibrosis (PMF) was being treated with hydroxyurea, which was changed to ruxolitinib treatment because of worsening constitutional symptoms." | ( Ikeda, M; Kiyasu, J; Ogawa, Y; Shiratsuchi, M; Tsuda, M; Tsukamoto, Y; Yufu, Y, 2018) |
| "In patients with myelofibrosis and thrombocytopenia, including those with prior anti-JAK therapy, pacritinib twice daily was more effective than BAT, including ruxolitinib, for reducing splenomegaly and symptoms." | ( Al-Fayoumi, S; Callahan, JA; Daly, R; Drummond, M; Gerds, AT; Gotlib, J; Granston, T; Gupta, V; Harrison, C; Hoffman, R; Jamieson, C; Mascarenhas, J; Mesa, R; Pristupa, A; Singer, JW; Stein, B; Szoke, A; Talpaz, M; Verstovsek, S, 2018) |
| "In 12 patients with myelofibrosis (median age, 63 years; range, 43 to 71 years) who were treated with ruxolitinib and underwent allogeneic stem cell transplantation (ASCT), ruxolitinib was continued (2 × 5 mg daily) until stable engraftment." | ( Ayuk, F; Badbaran, A; Christopeit, M; Kröger, N; Shahnaz Syed Abd Kadir, S; Wolschke, C; Zabelina, T, 2018) |
| "Treatment of patients with myelofibrosis with the type I JAK (Janus kinase) inhibitor ruxolitinib paradoxically induces JAK2 activation loop phosphorylation and is associated with a life-threatening cytokine-rebound syndrome if rapidly withdrawn." | ( Babon, JJ; Barry, EF; Dottore, M; Hercus, TR; Hughes, TP; Kan, WL; Lathi, M; Liau, NPD; Lopez, AF; Majeti, R; Parker, MW; Ross, DM; Stomski, F; Tergaonkar, V; Thomas, D; Tvorogov, D, 2018) |
| "The management of patients with myelofibrosis (MF) has dramatically changed since the introduction of ruxolitinib as a tailored treatment strategy." | ( Baratè, C; Benevolo, G; Bonifacio, M; Breccia, M; Elli, EM; Guglielmelli, P; Maffioli, M; Malato, A; Mendicino, F; Palandri, F; Palumbo, GA; Pugliese, N; Ricco, A; Rossi, E; Rumi, E; Sant'Antonio, E; Tiribelli, M, 2020) |
| "HS was treated with splenectomy." | ( Liu, H; Qian, J; Shen, Q; Shi, WY; Yang, L; Yin, H; Zhang, YP, 2019) |
| "Ruxolitinib is a targeted drug to treat myelofibrosis (MF)." | ( Hu, X; Li, Y; Liu, W; Ming, J; Wang, X; Zhu, S, 2020) |
| "Anemia in myelofibrosis (MF) occurs frequently, is poorly addressed by US Food and Drug Administration-approved JAK inhibitors, and negatively impacts quality of life." | ( Al Ali, N; Castillo-Tokumori, F; Komrokji, R; Kuykendall, AT; Lancet, J; Padron, E; Sallman, D; Sweet, K; Talati, C; Yun, S, 2020) |
| "Anemia is a frequent manifestation of myelofibrosis (MF) and there is an unmet need for effective treatments in anemic MF patients." | ( Al-Ali, HK; Cervantes, F; Foltz, L; Gilotti, G; Gisslinger, H; Komatsu, N; Mannelli, F; Myasnikov, A; Palandri, F; Passamonti, F; Radinoff, A; Ross, DM; Sadek, I; Tiwari, R; Vannucchi, AM; Zachee, P; Zor, E, 2021) |
| "Current therapy for myelofibrosis (MF) results in a limited prolongation of patient survival." | ( Clementelli, C; Elmansy, N; Hoffman, R; Lu, M; Tremblay, D; Xia, L, 2022) |
| "Mild-to-moderate bone marrow fibrosis was detected in the posttreatment biopsies of 12/22 patients (54." | ( Akyürek, N; Aydın Kaynar, L; Bostankolu Değirmenci, B; Dikyar, A; Özkurt, ZN; Uyar Göçün, P; Yegin, ZA, 2022) |
| "We report two cases of Primary Myelofibrosis who developed tuberculosis on active treatment with ruxolitinib." | ( Singh, A; Singh, B; Tiwari, N; Tripathi, AK; Verma, SP, 2022) |
| "The haematological assessment revealed myelofibrosis as the underlying disease, and treatment with ruxolitinib as the first-line choice was given by skipping hydroxyurea due to pancytopenia." | ( Deniz, R; Ezircan-Alay, M, 2023) |
| "Standard therapy for myelofibrosis comprises Janus kinase inhibitors (JAKis), yet spleen response rates of 30%-40%, high discontinuation rates, and a lack of disease modification highlight an unmet need." | ( Colak, G; Cui, J; Curto-García, N; Devos, T; Granacher, N; Gupta, V; Harrison, C; Hobbs, G; Hoffman, R; Kiladjian, JJ; Kremyanskaya, M; Mascarenhas, J; Mead, AJ; Palandri, F; Passamonti, F; Patriarca, A; Rampal, RK; Salama, ME; Scandura, JM; Somervaille, TCP; Talpaz, M; Vannucchi, AM; Verstovsek, S; Wondergem, MJ, 2023) |
| "People with myelofibrosis who receive treatment with ruxolitinib may need to stop treatment because it is not working or they cannot tolerate the side effects." | ( Mascarenhas, J; McBride, A; Nguyen, H; Oliver, L; Perry, R; Saunders, A; Tomkinson, H, 2023) |
| "The treatment of patients with myelofibrosis (MF) has evolved in the past decade, as reflected in an increased use of various therapeutic agents that could potentially impact patient outcomes." | ( Bose, P; Chifotides, HT; Daver, NG; Estrov, Z; Kantarjian, HM; Masarova, L; Pemmaraju, N; Sasaki, K; Verstovsek, S; Zhou, L, 2023) |
| "Outcomes of myelofibrosis (MF) with allogeneic stem cell transplantation (allo-SCT) have improved over the past decade, related in part to advances in supportive treatments and conditioning regimens." | ( Alousi, AM; Bashir, Q; Champlin, RE; Hosing, C; Joseph, J; Kebriaei, P; Milton, DR; Olson, AL; Oran, B; Popat, UR; Qazilbash, MH; Ramdial, JL; Saini, NY; Shpall, EJ; Srour, SA, 2023) |